Tonix Pharmaceuticals Holding (Tonix Pharmaceuticals Holding) Float Percentage Of Total Shares Outstanding : 100.00% (As of Apr. 28, 2024)

View and export this data going back to 2009. Start your Free Trial

What is Tonix Pharmaceuticals Holding Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Tonix Pharmaceuticals Holding's float shares is 95.54 Mil. Tonix Pharmaceuticals Holding's total shares outstanding is 95.54 Mil. Tonix Pharmaceuticals Holding's float percentage of total shares outstanding is 100.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Tonix Pharmaceuticals Holding's Insider Ownership is 4.21%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Tonix Pharmaceuticals Holding's Institutional Ownership is 1.26%.

Tonix Pharmaceuticals Holding Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Tonix Pharmaceuticals Holding's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	95.54	/	95.54
	=	100.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tonix Pharmaceuticals Holding (Tonix Pharmaceuticals Holding) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tonix Pharmaceuticals Holding Corp (NAS:TNXP) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

26 Main Street, Suite 101, Chatham, NJ, USA, 07928

Website

https://www.tonixpharma.com

Tonix Pharmaceuticals Holding Corp is a clinical-stage biopharmaceutical company focused on developing therapeutics and vaccines to treat and prevent human disease and alleviate suffering. its portfolio consists of the central nervous system, rare disease, immunology, and infectious disease product candidates. The CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. CNS product candidate is TNX-102 SL, a proprietary sublingual tablet formulation of cyclobenzaprine (CBP) designed for bedtime administration.

Executives

Richard Newcomb Stillwell	director	C/O TONIX PHARMACEUTICALS HOLDING CORP., 26 MAIN STREET, SUITE 101, CHATHAM NJ 07928
Seth Lederman	director, 10 percent owner, officer: Chief Executive Officer	C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Carolyn E. Taylor	director	C/O TONIX PHARMACEUTICALS HOLDING CORP., 26 MAIN STREET, SUITE 101, CHATHAM NJ 07928
Daniel Wintner Goodman	director	C/O TONIX PHARMACEUTICALS HOLDING CORP., 509 MADISON AVE, NEW YORK NY 10022
James Treco	director	C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., NEW YORK NY 10022
Margaret Smith Bell	director	C/O TONIX PHARMACEUTICALS HOLDING CORP., 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Gregory M Sullivan	officer: Chief Medical Officer	C/O TONIX PHARMACEUTICALS HOLDINGS CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Richard H Bagger	director	C/O TONIX PHARMACEUTICALS HOLDING CORP., 509 MADISON AVE. - SUITE 1608, NEW YORK NY 10022
Adeoye Y Olukotun	director	3621 SOUTH STATE ST, 695 KMS PL, ANN ARBOR MI 48108
David L Grange	director
Ernest Mario	director	20 FAIRMOUNT AVENUE, P.O. BOX 445, CHATHAM NJ 07928
Jessica Edgar Morris	officer: Chief Administrative Officer	C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Bradley Saenger	officer: Chief Financial Officer	C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
John B Rhodes	director	74 FIFTH AVENUE, NEW YORK NY 10011
Samuel R Saks	director	3180 PORTER DRIVE, PALO ALTO CA 94304